Medical Care
Global Duchenne Muscular Dystrophy Drugs Market Research Report 2025
- Sep 06, 25
- ID: 491051
- Pages: 82
- Figures: 88
- Views: 51
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy Drugs.
The Duchenne Muscular Dystrophy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Segment by Type
Molecular-based Therapies
Steroid Therapy
Other
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Duchenne Muscular Dystrophy Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Segment by Type
Molecular-based Therapies
Steroid Therapy
Other
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Molecular-based Therapies
1.2.3 Steroid Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2020-2031)
2.2 Global Duchenne Muscular Dystrophy Drugs Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Size by Region (2020-2025)
2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2026-2031)
2.3 Duchenne Muscular Dystrophy Drugs Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Drugs Industry Trends
2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy Drugs Revenue
3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2024
3.5 Global Key Players of Duchenne Muscular Dystrophy Drugs Head office and Area Served
3.6 Global Key Players of Duchenne Muscular Dystrophy Drugs, Product and Application
3.7 Global Key Players of Duchenne Muscular Dystrophy Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2020-2025)
4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2026-2031)
5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2020-2025)
5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
6.2 North America Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
6.4 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
7.4 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
9.4 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.1.5 Biogen Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Details
11.3.2 Daiichi Sankyo Business Overview
11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.3.5 Daiichi Sankyo Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.4.5 Pfizer Recent Development
11.5 Cumberland Pharmaceuticals
11.5.1 Cumberland Pharmaceuticals Company Details
11.5.2 Cumberland Pharmaceuticals Business Overview
11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.5.5 Cumberland Pharmaceuticals Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.6.5 Santhera Pharmaceuticals Recent Development
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Details
11.7.2 Taiho Pharmaceutical Business Overview
11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.7.5 Taiho Pharmaceutical Recent Development
11.8 Teijin Pharma
11.8.1 Teijin Pharma Company Details
11.8.2 Teijin Pharma Business Overview
11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.8.5 Teijin Pharma Recent Development
11.9 Akashi Therapeutics
11.9.1 Akashi Therapeutics Company Details
11.9.2 Akashi Therapeutics Business Overview
11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.9.5 Akashi Therapeutics Recent Development
11.10 Sarepta Therapeutics
11.10.1 Sarepta Therapeutics Company Details
11.10.2 Sarepta Therapeutics Business Overview
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.10.5 Sarepta Therapeutics Recent Development
11.11 BioMarin
11.11.1 BioMarin Company Details
11.11.2 BioMarin Business Overview
11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.11.5 BioMarin Recent Development
11.12 Fibrogen Inc
11.12.1 Fibrogen Inc Company Details
11.12.2 Fibrogen Inc Business Overview
11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.12.5 Fibrogen Inc Recent Development
11.13 Nobelpharma Co. Ltd
11.13.1 Nobelpharma Co. Ltd Company Details
11.13.2 Nobelpharma Co. Ltd Business Overview
11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.13.5 Nobelpharma Co. Ltd Recent Development
11.14 Eloxx Pharmaceuticals
11.14.1 Eloxx Pharmaceuticals Company Details
11.14.2 Eloxx Pharmaceuticals Business Overview
11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.14.5 Eloxx Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Molecular-based Therapies
1.2.3 Steroid Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2020-2031)
2.2 Global Duchenne Muscular Dystrophy Drugs Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Size by Region (2020-2025)
2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2026-2031)
2.3 Duchenne Muscular Dystrophy Drugs Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Drugs Industry Trends
2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy Drugs Revenue
3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2024
3.5 Global Key Players of Duchenne Muscular Dystrophy Drugs Head office and Area Served
3.6 Global Key Players of Duchenne Muscular Dystrophy Drugs, Product and Application
3.7 Global Key Players of Duchenne Muscular Dystrophy Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2020-2025)
4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2026-2031)
5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2020-2025)
5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
6.2 North America Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
6.4 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
7.4 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
9.4 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2020-2031)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.1.5 Biogen Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Details
11.3.2 Daiichi Sankyo Business Overview
11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.3.5 Daiichi Sankyo Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.4.5 Pfizer Recent Development
11.5 Cumberland Pharmaceuticals
11.5.1 Cumberland Pharmaceuticals Company Details
11.5.2 Cumberland Pharmaceuticals Business Overview
11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.5.5 Cumberland Pharmaceuticals Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.6.5 Santhera Pharmaceuticals Recent Development
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Details
11.7.2 Taiho Pharmaceutical Business Overview
11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.7.5 Taiho Pharmaceutical Recent Development
11.8 Teijin Pharma
11.8.1 Teijin Pharma Company Details
11.8.2 Teijin Pharma Business Overview
11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.8.5 Teijin Pharma Recent Development
11.9 Akashi Therapeutics
11.9.1 Akashi Therapeutics Company Details
11.9.2 Akashi Therapeutics Business Overview
11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.9.5 Akashi Therapeutics Recent Development
11.10 Sarepta Therapeutics
11.10.1 Sarepta Therapeutics Company Details
11.10.2 Sarepta Therapeutics Business Overview
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.10.5 Sarepta Therapeutics Recent Development
11.11 BioMarin
11.11.1 BioMarin Company Details
11.11.2 BioMarin Business Overview
11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.11.5 BioMarin Recent Development
11.12 Fibrogen Inc
11.12.1 Fibrogen Inc Company Details
11.12.2 Fibrogen Inc Business Overview
11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.12.5 Fibrogen Inc Recent Development
11.13 Nobelpharma Co. Ltd
11.13.1 Nobelpharma Co. Ltd Company Details
11.13.2 Nobelpharma Co. Ltd Business Overview
11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.13.5 Nobelpharma Co. Ltd Recent Development
11.14 Eloxx Pharmaceuticals
11.14.1 Eloxx Pharmaceuticals Company Details
11.14.2 Eloxx Pharmaceuticals Business Overview
11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
11.14.5 Eloxx Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Molecular-based Therapies
Table 3. Key Players of Steroid Therapy
Table 4. Key Players of Other
Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2020-2025)
Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2026-2031)
Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players (2020-2025)
Table 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2024)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Duchenne Muscular Dystrophy Drugs, Headquarters and Area Served
Table 21. Global Key Players of Duchenne Muscular Dystrophy Drugs, Product and Application
Table 22. Global Key Players of Duchenne Muscular Dystrophy Drugs, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2020-2025)
Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2026-2031)
Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2020-2025)
Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2026-2031)
Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 47. Biogen Company Details
Table 48. Biogen Business Overview
Table 49. Biogen Duchenne Muscular Dystrophy Drugs Product
Table 50. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 51. Biogen Recent Development
Table 52. Roche Company Details
Table 53. Roche Business Overview
Table 54. Roche Duchenne Muscular Dystrophy Drugs Product
Table 55. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 56. Roche Recent Development
Table 57. Daiichi Sankyo Company Details
Table 58. Daiichi Sankyo Business Overview
Table 59. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
Table 60. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 61. Daiichi Sankyo Recent Development
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Duchenne Muscular Dystrophy Drugs Product
Table 65. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Cumberland Pharmaceuticals Company Details
Table 68. Cumberland Pharmaceuticals Business Overview
Table 69. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 70. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 71. Cumberland Pharmaceuticals Recent Development
Table 72. Santhera Pharmaceuticals Company Details
Table 73. Santhera Pharmaceuticals Business Overview
Table 74. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 75. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 76. Santhera Pharmaceuticals Recent Development
Table 77. Taiho Pharmaceutical Company Details
Table 78. Taiho Pharmaceutical Business Overview
Table 79. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
Table 80. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 81. Taiho Pharmaceutical Recent Development
Table 82. Teijin Pharma Company Details
Table 83. Teijin Pharma Business Overview
Table 84. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product
Table 85. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 86. Teijin Pharma Recent Development
Table 87. Akashi Therapeutics Company Details
Table 88. Akashi Therapeutics Business Overview
Table 89. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 90. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 91. Akashi Therapeutics Recent Development
Table 92. Sarepta Therapeutics Company Details
Table 93. Sarepta Therapeutics Business Overview
Table 94. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 95. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 96. Sarepta Therapeutics Recent Development
Table 97. BioMarin Company Details
Table 98. BioMarin Business Overview
Table 99. BioMarin Duchenne Muscular Dystrophy Drugs Product
Table 100. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 101. BioMarin Recent Development
Table 102. Fibrogen Inc Company Details
Table 103. Fibrogen Inc Business Overview
Table 104. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product
Table 105. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 106. Fibrogen Inc Recent Development
Table 107. Nobelpharma Co. Ltd Company Details
Table 108. Nobelpharma Co. Ltd Business Overview
Table 109. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product
Table 110. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 111. Nobelpharma Co. Ltd Recent Development
Table 112. Eloxx Pharmaceuticals Company Details
Table 113. Eloxx Pharmaceuticals Business Overview
Table 114. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 115. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 116. Eloxx Pharmaceuticals Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
Table 120. Authors List of This Report
List of Figures
Figure 1. Duchenne Muscular Dystrophy Drugs Picture
Figure 2. Global Duchenne Muscular Dystrophy Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2024 VS 2031
Figure 4. Molecular-based Therapies Features
Figure 5. Steroid Therapy Features
Figure 6. Other Features
Figure 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Duchenne Muscular Dystrophy Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Duchenne Muscular Dystrophy Drugs Market Share by Region: 2024 VS 2031
Figure 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2024
Figure 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2024
Figure 19. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 21. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 25. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Region (2020-2031)
Figure 33. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 41. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 45. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 49. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 50. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 51. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 52. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 53. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 54. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 55. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 56. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 57. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 58. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 59. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 60. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 61. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Molecular-based Therapies
Table 3. Key Players of Steroid Therapy
Table 4. Key Players of Other
Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2020-2025)
Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2026-2031)
Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players (2020-2025)
Table 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2024)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Duchenne Muscular Dystrophy Drugs, Headquarters and Area Served
Table 21. Global Key Players of Duchenne Muscular Dystrophy Drugs, Product and Application
Table 22. Global Key Players of Duchenne Muscular Dystrophy Drugs, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2020-2025)
Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2026-2031)
Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2020-2025)
Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2026-2031)
Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 47. Biogen Company Details
Table 48. Biogen Business Overview
Table 49. Biogen Duchenne Muscular Dystrophy Drugs Product
Table 50. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 51. Biogen Recent Development
Table 52. Roche Company Details
Table 53. Roche Business Overview
Table 54. Roche Duchenne Muscular Dystrophy Drugs Product
Table 55. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 56. Roche Recent Development
Table 57. Daiichi Sankyo Company Details
Table 58. Daiichi Sankyo Business Overview
Table 59. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
Table 60. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 61. Daiichi Sankyo Recent Development
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Duchenne Muscular Dystrophy Drugs Product
Table 65. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Cumberland Pharmaceuticals Company Details
Table 68. Cumberland Pharmaceuticals Business Overview
Table 69. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 70. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 71. Cumberland Pharmaceuticals Recent Development
Table 72. Santhera Pharmaceuticals Company Details
Table 73. Santhera Pharmaceuticals Business Overview
Table 74. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 75. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 76. Santhera Pharmaceuticals Recent Development
Table 77. Taiho Pharmaceutical Company Details
Table 78. Taiho Pharmaceutical Business Overview
Table 79. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
Table 80. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 81. Taiho Pharmaceutical Recent Development
Table 82. Teijin Pharma Company Details
Table 83. Teijin Pharma Business Overview
Table 84. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product
Table 85. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 86. Teijin Pharma Recent Development
Table 87. Akashi Therapeutics Company Details
Table 88. Akashi Therapeutics Business Overview
Table 89. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 90. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 91. Akashi Therapeutics Recent Development
Table 92. Sarepta Therapeutics Company Details
Table 93. Sarepta Therapeutics Business Overview
Table 94. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 95. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 96. Sarepta Therapeutics Recent Development
Table 97. BioMarin Company Details
Table 98. BioMarin Business Overview
Table 99. BioMarin Duchenne Muscular Dystrophy Drugs Product
Table 100. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 101. BioMarin Recent Development
Table 102. Fibrogen Inc Company Details
Table 103. Fibrogen Inc Business Overview
Table 104. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product
Table 105. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 106. Fibrogen Inc Recent Development
Table 107. Nobelpharma Co. Ltd Company Details
Table 108. Nobelpharma Co. Ltd Business Overview
Table 109. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product
Table 110. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 111. Nobelpharma Co. Ltd Recent Development
Table 112. Eloxx Pharmaceuticals Company Details
Table 113. Eloxx Pharmaceuticals Business Overview
Table 114. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 115. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2020-2025) & (US$ Million)
Table 116. Eloxx Pharmaceuticals Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
Table 120. Authors List of This Report
List of Figures
Figure 1. Duchenne Muscular Dystrophy Drugs Picture
Figure 2. Global Duchenne Muscular Dystrophy Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2024 VS 2031
Figure 4. Molecular-based Therapies Features
Figure 5. Steroid Therapy Features
Figure 6. Other Features
Figure 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Duchenne Muscular Dystrophy Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Duchenne Muscular Dystrophy Drugs Market Share by Region: 2024 VS 2031
Figure 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2024
Figure 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2024
Figure 19. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 21. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 25. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Region (2020-2031)
Figure 33. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 41. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Country (2020-2031)
Figure 45. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 49. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 50. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 51. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 52. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 53. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 54. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 55. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 56. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 57. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 58. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 59. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 60. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 61. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232